Reimagining Anticoagulation Clinics in the Era of Direct Oral Anticoagulants

Circulation: Cardiovascular Quality and Outcomes

Volumn 9, Issue 2, 2016, Pages 182-185

  Barnes, Geoffrey D ^a   Nallamothu, Brahmajee K ^a   Sales, Anne E ^a   Froehlich, James B ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

anticoagulant; anticoagulation; nurse management; pharmacist management; warfarin

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; SPIRONOLACTONE; WARFARIN;

ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; DRUG EFFICACY; DRUG REPOSITIONING; HEART VALVE REPLACEMENT; HUMAN; MEDICATION COMPLIANCE; PRIORITY JOURNAL; RISK REDUCTION; VENOUS THROMBOEMBOLISM; BLOOD CLOTTING; BLOOD CLOTTING TEST; CHEMICALLY INDUCED; DOSE CALCULATION; DRUG EFFECTS; DRUG MONITORING; INTEGRATED HEALTH CARE SYSTEM; ORAL DRUG ADMINISTRATION; ORGANIZATION AND MANAGEMENT; OUTPATIENT DEPARTMENT; PATIENT SELECTION; PREDICTIVE VALUE; PROCEDURES; RISK FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AMBULATORY CARE FACILITIES; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DELIVERY OF HEALTH CARE, INTEGRATED; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; HEMORRHAGE; HUMANS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84962582051     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.115.002366     Document Type: Article

References (15)

1. Rudd KM, Dier JG., Comparison of two different models of anticoagulation management services with usual medical care. Pharmacotherapy 2010 30 330 338. doi: 10.1592/phco.30.4.330.
2. Barnes GD, Lucas E, Alexander GC, Goldberger ZD., National trends in ambulatory oral anticoagulant use. Am J Med 2015 128 1300 1305.e2. doi: 10.1016/j.amjmed.2015.05.044.
3. Barnes GD, Ageno W, Ansell J, Kaatz S, Subcommittee on the Control of Anticoagulation Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH. J Thromb Haemost 2015 13 1154 1156. doi: 10.1111/jth.12969.
4. Salata BM, Hutton DW, Levine DA, Froehlich JB, Barnes GD., Cost-Effectiveness of dabigatran (150 mg twice daily) and warfarin in patients ≥65 years with nonvalvular atrial fibrillation. Am J Cardiol 2016 117 54 60. doi: 10.1016/j.amjcard.2015.09.048.
5. Shore S, Ho PM, Lambert-Kerzner A, Glorioso TJ, Carey EP, Cunningham F, Longo L, Jackevicius C, Rose A, Turakhia MP., Site-level variation in and practices associated with dabigatran adherence. JAMA 2015 313 1443 1450. doi: 10.1001/jama.2015.2761.
6. Roldán V, Marín F, Fernández H, Manzano-Fernández S, Gallego P, Valdés M, Vicente V, Lip GY., Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol 2013 111 1159 1164. doi: 10.1016/j.amjcard.2012.12.045.
7. Steinberg BA, Peterson ED, Kim S, Thomas L, Gersh BJ, Fonarow GC, Kowey PR, Mahaffey KW, Sherwood MW, Chang P, Piccini JP, Ansell J, Outcomes Registry for Better Informed Treatment of Atrial Fibrillation Investigators and Patients Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circulation 2015 131 488 494. doi: 10.1161/CIRCULATIONAHA.114.011777.
8. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER III, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB, American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation 2015 131 e29 322. doi: 10.1161/CIR.0000000000000152.
9. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P., EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013 34 2094 2106. doi: 10.1093/eurheartj/eht134.
10. Falconieri L, Thomson L, Oettinger G, Pugliese R, Palladino M, Galanis T, Merli G., Facilitating anticoagulation for safer transitions: preliminary outcomes from an emergency department deep vein thrombosis discharge program. Hosp Pract (1995) 2014 42 16 45. doi: 10.3810/hp.2014.10.1140.
11. Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, Garcia DA, Jacobson A, Jaffer AK, Kong DF, Schulman S, Turpie AG, Hasselblad V, Ortel TL, BRIDGE Investigators Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 2015 373 823 833. doi: 10.1056/NEJMoa1501035.
12. Cooper LB, Hammill BG, Peterson ED, Pitt B, Maciejewski ML, Curtis LH, Hernandez AF., Consistency of laboratory monitoring during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure. JAMA 2015 314 1973 1975. doi: 10.1001/jama.2015.11904.
13. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA., Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004 351 543 551. doi: 10.1056/NEJMoa040135.
14. Raebel MA, Carroll NM, Simon SR, Andrade SE, Feldstein AC, Lafata JE, Nelson WW, Chan KA, Gunter MJ, Tolsma D, Platt R., Liver and thyroid monitoring in ambulatory patients prescribed amiodarone in 10 HMOs. J Manag Care Pharm 2006 12 656 664
15. Spence MM, Polzin JK, Weisberger CL, Martin JP, Rho JP, Willick GH., Evaluation of a pharmacist-managed amiodarone monitoring program. J Manag Care Pharm 2011 17 513 522